Skip to content

Plasma lipoproteins in coronary artery disease.

Redox signaling, Beta 2 Glycoprotein 1 and plasma lipoproteins in coronary artery disease.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12616001312437
Acronym
PLACARD (PLasmA lipoproteins in Coronary ArteRy Disease)
Enrollment
795
Registered
2016-09-19
Start date
2016-09-19
Completion date
2018-05-29
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

In this prospective observational study, we are investigating the association between blood proteins (beta-2-glycoprotein I, Apo B100 and HDL) and coronary artery disease as well as complications after percutaneous coronary intervention (stenting or ballooning) and late graft failure after coronary artery bypass grafting.

Interventions

1. To investigate the association between post translational forms of circulating plasma lipoproteins, beta-2-glycoprotein I, HDL and ApoB100, and atherosclerotic coronary disease. 2. To investigate the association between post translational forms of circulating plasma lipoproteins, beta-2-glycoprotein I, HDL and ApoB100, and clinical presentation with atherothrombotic acute coronary disease. 3. To investigate the association between post translational forms of circulating plasma lipoproteins,

1. To investigate the association between post translational forms of circulating plasma lipoproteins, beta-2-glycoprotein I, HDL and ApoB100, and atherosclerotic coronary disease. 2. To investigate the association between post translational forms of circulating plasma lipoproteins, beta-2-glycoprotein I, HDL and ApoB100, and clinical presentation with atherothrombotic acute coronary disease. 3. To investigate the association between post translational forms of circulating plasma lipoproteins, beta-2-glycoprotein I, HDL and ApoB100, and complications after percutaneous coronary intervention and late graft failure after CABG. The patients having angiography or CT angiography, a 15 ml blood sample shall be collected at the time of procedure. Out of this group, the patients who did not have ACS and have stent implantation shall have second blood sample 3 hours post procedure. The patients presenting with ST elevation myocardial infarction will have collection of only one blood sample 24 hours after the stent implantation. Clinical follow up shall be performed by phone interview at 30 days 12 months and at 2 years.

Sponsors

St George Hospital
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All patients recommended to have CT coronary angiography or coronary angiography will be recruited. Pre specified subgroup analysis will be performed based upon angiographic findings and clinical presentation. Willing to provide informed consent.

Exclusion criteria

1. Severe valvular disease. 2. Thrombolysis in last one week 3. Previously enrolled in this study 4. Active sepsis 5. Nephrotic syndrome 6. End stage renal failure on dialysis 7. Severe liver disease (Child-Pugh C) 8. Current pregnancy 9. Previously documented Antiphospholipid Antibody Syndrome 10. Active malignancy 11. Cerebrovascular accident in the last 3 months

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026